Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Head and Neck Tumors DNA Detected in Body Fluids

By LabMedica International staff writers
Posted on 06 Jul 2015
The potential of tumor-specific DNA as a biomarker for head and neck squamous cell carcinomas (HNSCC) has been explored in both saliva and blood samples.

Although HNSCC tumors are usually classified on the basis of histology, their biomedical properties, including demographics, risks factors, and clinical behavior, differ by anatomical site. More...


Cancer specialist at different institutes and led by those at Johns Hopkins University School of Medicine (Baltimore, MD, USA) studied 93 patients with newly diagnosed and recurrent head and neck cancer who gave saliva samples and 47 of them also donated blood samples before their treatment. Saliva was collected using two different protocols and blood samples were processed for plasma. When fresh tumor tissue from a surgical specimen of invasive SCC was available, it was immediately frozen at −80 °C. When frozen tissue was not available, formalin-fixed, paraffin-embedded (FFPE) tissues were used for DNA purification.

The teams also searched for somatic mutations or human papillomavirus (HPV) genes, collectively referred to as tumor DNA. Massively parallel sequencing was carried out on a HiSeq instrument (Illumina; San Diego, CA, USA). When no HPV was present, multiplex polymerase chain reactions (PCRs) containing primers amplifying regions of interest in six cancer-related genes that were used to identify driver mutations in the tumors. Blood tests correctly identified HPV-related tumors, occurring in 30 of the 93 patients, more often than saliva tests, probably because HPV-related tumors tend to occur in the back of the throat, which may not have been reached with the saliva rinse.

The scientists detected tumor DNA in the saliva of 71 of the 93 patients (76%) and in the blood of 41 of the 47 (87%). In the 47 who gave blood and saliva samples, scientists were able to detect tumor DNA in at least one of the body fluids in 45 of them (96%). Blood tests correctly identified tumor DNA more often in 20 of 22 oropharynx cancers (91%), six of seven larynx cancers (86%) and all three hypopharynx cancers. Taken together, blood and saliva tests correctly identified all oral cavity, larynx and hypopharynx cancers and 20 of 22 oropharynx cancers (91%).

Nishant Agrawal, MD, an associate professor of otolaryngology and senior author of the study said, “We have shown that tumor DNA in the blood or saliva can successfully be measured for these cancers. In our study, testing saliva seemed to be the best way to detect cancers in the oral cavity, and blood tests appeared to find more cancers in the larynx, hypopharynx and oropharynx. However, combining blood and saliva tests may offer the best chance of finding cancer in any of those regions.” The study was published on June 24, 2015, in the journal Science Translational Medicine.

Related Links:

Johns Hopkins University School of Medicine
Illumina



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.